Eevia Health Secures Major Bilberry Extract Order

Eevia Health Plc, a leader in sustainable bioactive compounds, has announced a substantial new order for its flagship product, Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins. This order was placed by a prominent Swedish brand owner with a retail presence in over 50,000 outlets across 38 countries, highlighting Eevia's growing influence in the global market. The deliveries are scheduled for April and May, ensuring a timely fulfillment.

In addition to this major order, Eevia has also secured contracts from clients in Finland, the United States, and a new customer in France. These orders include Feno-Cerasus™ 5 Organic, a tart cherry extract, Fenoprolic™ 70 Organic, a pine bark extract, and Feno-Vitis™ 5 Organic, a lingonberry extract. The total value of these sales orders is KEUR 130.

What makes this development particularly significant is Eevia's strategic use of its inventory. With most product volumes already in stock, the company can ensure immediate shipments, thereby avoiding potential delays in raw material procurement. This approach not only supports Eevia's cash flow improvements but also aligns with its turnaround strategy by reducing stock levels.

Eevia Health's commitment to expanding its footprint in Europe and beyond is evident in these recent orders. The company's focus on high-quality, organically certified plant extracts positions it well in the growing health and wellness industry. Furthermore, its modern green-chemistry production facility in Finland underscores its dedication to sustainability and environmental responsibility.

Given these positive developments and Eevia's strategic initiatives, the outlook for the company appears promising. Investors might consider this an opportune moment to hold their positions, as Eevia continues to leverage its growing customer base to drive sustained growth.